{"transactions":[{"id":713663,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Restricted Stock Units","published_at":"2026-07-08T00:00:04.000Z","date":"2026-07-03","kind":"exercise","planned":false,"acquired":false,"shares":680,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date."}],"balance_after":640,"derivative":{"underlying":"Common Stock","underlying_shares":680},"source":{"system":"sec-edgar","filing":"0001193125-26-297818","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000119312526297818/ownership.xml","form_type":"4"}},{"id":713662,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-07-08T00:00:04.000Z","date":"2026-07-06","kind":"sale","planned":false,"acquired":false,"shares":245,"price":29.98,"value":7345.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person."}],"balance_after":2289,"source":{"system":"sec-edgar","filing":"0001193125-26-297818","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000119312526297818/ownership.xml","form_type":"4"}},{"id":713661,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-07-08T00:00:04.000Z","date":"2026-07-03","kind":"exercise","planned":false,"acquired":true,"shares":680,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date."}],"balance_after":2534,"source":{"system":"sec-edgar","filing":"0001193125-26-297818","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000119312526297818/ownership.xml","form_type":"4"}},{"id":828256,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-25T22:09:57.000Z","date":"2026-03-23","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase shares of common stock of the Issuer. This option will vest as to 25% on March 23, 2027 and in equal monthly installments thereafter through March 23, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":250000,"derivative":{"exercise_price":23.05,"expiration_date":"2036-03-23","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001193125-26-124487","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000119312526124487/ownership.xml","form_type":"4"}},{"id":946905,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Restricted Stock Units","published_at":"2026-01-06T21:30:13.000Z","date":"2026-01-02","kind":"exercise","planned":false,"acquired":false,"shares":680,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date."}],"balance_after":1320,"derivative":{"underlying":"Common Stock","underlying_shares":680},"source":{"system":"sec-edgar","filing":"0001193125-26-004568","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000119312526004568/ownership.xml","form_type":"4"}},{"id":946904,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-01-06T21:30:13.000Z","date":"2026-01-02","kind":"sale","planned":false,"acquired":false,"shares":255,"price":21.38,"value":5451.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person."}],"balance_after":1854,"source":{"system":"sec-edgar","filing":"0001193125-26-004568","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000119312526004568/ownership.xml","form_type":"4"}},{"id":946903,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-01-06T21:30:13.000Z","date":"2026-01-02","kind":"exercise","planned":false,"acquired":true,"shares":680,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date."}],"balance_after":2109,"source":{"system":"sec-edgar","filing":"0001193125-26-004568","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000119312526004568/ownership.xml","form_type":"4"}},{"id":1090670,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Restricted Stock Units","published_at":"2025-07-08T20:00:06.000Z","date":"2025-07-03","kind":"exercise","planned":false,"acquired":false,"shares":680,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date."}],"balance_after":2000,"derivative":{"underlying":"Common Stock","underlying_shares":680},"source":{"system":"sec-edgar","filing":"0000950170-25-094575","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000095017025094575/ownership.xml","form_type":"4"}},{"id":1090669,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2025-07-08T20:00:06.000Z","date":"2025-07-03","kind":"sale","planned":false,"acquired":false,"shares":260,"price":3.39,"value":881.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person."}],"balance_after":1429,"source":{"system":"sec-edgar","filing":"0000950170-25-094575","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000095017025094575/ownership.xml","form_type":"4"}},{"id":1090668,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2025-07-08T20:00:06.000Z","date":"2025-07-03","kind":"exercise","planned":false,"acquired":true,"shares":680,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date."}],"balance_after":1689,"source":{"system":"sec-edgar","filing":"0000950170-25-094575","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000095017025094575/ownership.xml","form_type":"4"}},{"id":1308182,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-07T21:00:07.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to such option will vest and become exercisable on January 3, 2026 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":6000,"derivative":{"exercise_price":5.7,"expiration_date":"2035-01-03","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0000950170-25-002814","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000095017025002814/ownership.xml","form_type":"4"}},{"id":1308181,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Restricted Stock Units","published_at":"2025-01-07T21:00:07.000Z","date":"2025-01-03","kind":"exercise","planned":false,"acquired":false,"shares":1320,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date."}],"balance_after":2680,"derivative":{"underlying":"Common Stock","underlying_shares":1320},"source":{"system":"sec-edgar","filing":"0000950170-25-002814","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000095017025002814/ownership.xml","form_type":"4"}},{"id":1308180,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2025-01-07T21:00:07.000Z","date":"2025-01-03","kind":"sale","planned":false,"acquired":false,"shares":471,"price":5.6,"value":2637.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person."}],"balance_after":1009,"source":{"system":"sec-edgar","filing":"0000950170-25-002814","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000095017025002814/ownership.xml","form_type":"4"}},{"id":1308179,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2025-01-07T21:00:07.000Z","date":"2025-01-03","kind":"exercise","planned":false,"acquired":true,"shares":1320,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date."}],"balance_after":1480,"source":{"system":"sec-edgar","filing":"0000950170-25-002814","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000095017025002814/ownership.xml","form_type":"4"}},{"id":1387593,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2024-10-11T21:00:04.000Z","date":"2024-10-09","kind":"grant","planned":false,"acquired":true,"shares":15600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to such option vest in 48 equal monthly installments over four years from the Award Date, subject in each case to the grantee's continued service through the applicable vesting date."}],"balance_after":15600,"derivative":{"exercise_price":7.49,"expiration_date":"2034-10-09","underlying":"Common Stock","underlying_shares":15600},"source":{"system":"sec-edgar","filing":"0000950170-24-114387","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000095017024114387/ownership.xml","form_type":"4"}},{"id":1685584,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Restricted Stock Units","published_at":"2024-01-05T21:00:09.000Z","date":"2024-01-03","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit represents the right to receive, at settlement, one share of common stock of Galecto, Inc.  One-third of the restricted stock units subject to the award will vest on January 3, 2025 and the remaining restricted stock units will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents the right to receive, at settlement, one share of common stock of Galecto, Inc.  One-third of the restricted stock units subject to the award will vest on January 3, 2025 and the remaining restricted stock units will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date."}],"balance_after":100000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950170-24-002429","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000095017024002429/ownership.xml","form_type":"4"}},{"id":2062971,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-05T21:00:26.000Z","date":"2023-01-04","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vested and became exercisable on January 4, 2024 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":80000,"derivative":{"exercise_price":1.21,"expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001209191-23-001758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000120919123001758/doc4.xml","form_type":"4"}},{"id":2441738,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-06T22:00:30.000Z","date":"2022-01-04","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vested and became exercisable on January 4, 2023 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":75000,"derivative":{"exercise_price":3.24,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-22-002213","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000120919122002213/doc4.xml","form_type":"4"}},{"id":2483971,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2021-12-06T13:00:12.000Z","date":"2021-12-03","kind":"purchase","acquired":true,"shares":2000,"price":2.48,"value":4960.0,"ownership":{"direct":true},"balance_after":4000,"source":{"system":"sec-edgar","filing":"0001209191-21-068028","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000120919121068028/doc4.xml","form_type":"4"}},{"id":2657480,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2021-06-23T20:00:11.000Z","date":"2021-06-23","kind":"purchase","acquired":true,"shares":2000,"price":4.8,"value":9600.0,"ownership":{"direct":true},"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001209191-21-042718","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000120919121042718/doc4.xml","form_type":"4"}},{"id":2666463,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2021-06-16T21:00:15.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option will vest and become exercisable on May 2, 2022 and the remainder of the shares will vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":120000,"derivative":{"exercise_price":5.61,"expiration_date":"2031-06-14","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001209191-21-040944","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000120919121040944/doc4.xml","form_type":"4"}},{"id":2970036,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Restricted Stock Units","published_at":"2020-11-23T16:14:44.000Z","date":"2020-11-19","kind":"exercise","acquired":false,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") converted into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All unvested issued and outstanding RSUs accelerated and vested in full in connection with the closing of the business combination with F-star Therapeutics Limited."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"All unvested issued and outstanding RSUs accelerated and vested in full in connection with the closing of the business combination with F-star Therapeutics Limited."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0000905718-20-001132","document":"springbank_fm4nov192020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000090571820001132/springbank_fm4nov192020.xml","form_type":"4"}},{"id":2970035,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Stock","published_at":"2020-11-23T16:14:44.000Z","date":"2020-11-20","kind":"sale","acquired":false,"shares":175,"price":4.76,"value":833.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.64 to $4.88 per share. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."}],"balance_after":18575,"source":{"system":"sec-edgar","filing":"0000905718-20-001132","document":"springbank_fm4nov192020.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000090571820001132/springbank_fm4nov192020.xml","form_type":"4"}},{"id":2970034,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Stock","published_at":"2020-11-23T16:14:44.000Z","date":"2020-11-19","kind":"grant","acquired":true,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") converted into common stock on a one-for-one basis."}],"balance_after":18750,"source":{"system":"sec-edgar","filing":"0000905718-20-001132","document":"springbank_fm4nov192020.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000090571820001132/springbank_fm4nov192020.xml","form_type":"4"}},{"id":2970033,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Stock","published_at":"2020-11-23T16:14:44.000Z","date":"2020-11-19","kind":"exercise","acquired":true,"shares":6250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") converted into common stock on a one-for-one basis."}],"balance_after":6250,"source":{"system":"sec-edgar","filing":"0000905718-20-001132","document":"springbank_fm4nov192020.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000090571820001132/springbank_fm4nov192020.xml","form_type":"4"}},{"id":3220754,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Restricted Stock Units","published_at":"2020-03-09T20:15:11.000Z","date":"2020-03-05","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Spring Bank Pharmaceuticals, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units will vest in two installments. Fifty percent will vest on March 5, 2021 and the remaining fifty percent will vest on December 31, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units will vest in two installments. Fifty percent will vest on March 5, 2021 and the remaining fifty percent will vest on December 31, 2021."}],"balance_after":25000,"derivative":{"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-20-017242","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000120919120017242/doc4.xml","form_type":"4"}},{"id":3220753,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":31705,"kind":"person","name":"Winslow Garrett","position":1,"cik":"0001803773","reported_name":"Winslow Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-09T20:15:11.000Z","date":"2020-03-05","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on March 5, 2020, with 25% of the shares subject to the option vesting on March 5, 2021 and the remaining 75% of the shares subject to the option vesting in 36 equal monthly installments thereafter."}],"balance_after":25000,"derivative":{"exercise_price":1.41,"expiration_date":"2030-03-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-20-017242","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803773/000120919120017242/doc4.xml","form_type":"4"}}]}